Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019

Rattanawong, Pattara; Shen, Win Kuang; Masry, Hicham El; Sorajja, Dan; Srivathsan, Komandoor; Valverde, Arturo M.; Scott, Luis R.

doi:10.1161/jaha.120.017529

Cited by 37 publications

(56 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rhythm control strategy can be achieved with synchronized cardioversion or AAD medications like amiodarone; however, close monitoring with caution is recommended with the use of amiodarone in patients undergoing treatment with fingolimod. Propafenone or flecainide is preferred in structurally normal hearts who are on fingolimod ( 63 ). Transthoracic echocardiography (TTE) is recommended only in hemodynamically unstable patients.…”

Section: Management Of Arrhythmias With Covid-19mentioning

confidence: 99%

Arrhythmias and COVID-19

Dherange

Lang

Qian

et al. 2020

JACC: Clinical Electrophysiology

151

156

View full text Add to dashboard Cite

Current understanding of the impact of coronavirus disease-2019 (COVID-19) on arrhythmias continues to evolve as new data emerge. Cardiac arrhythmias are more common in critically ill COVID-19 patients. The potential mechanisms that could result in arrhythmogenesis among COVID-19 patients include hypoxia caused by direct viral tissue involvement of lungs, myocarditis, abnormal host immune response, myocardial ischemia, myocardial strain, electrolyte derangements, intravascular volume imbalances, and drug sides effects. To manage these arrhythmias, it is imperative to increase the awareness of potential drug-drug interactions, to monitor QTc prolongation while receiving COVID therapy and provide special considerations for patients with inherited arrhythmia syndromes. It is also crucial to minimize exposure to COVID-19 infection by stratifying the need for intervention and using telemedicine. As COVID-19 infection continues to prevail with a potential for future surges, more data are required to better understand pathophysiology and to validate management strategies.

show abstract

Section: Management Of Arrhythmias With Covid-19mentioning

confidence: 99%

Arrhythmias and COVID-19

Dherange

Lang

Qian

et al. 2020

JACC: Clinical Electrophysiology

151

156

View full text Add to dashboard Cite

show abstract

“…The usage of antiarrhythmics for prophylaxis of VT/VF for patients during COVID infection is unclear, especially since it is still not known why some patient have cardiac arrhythmic complications and others do not. Usage of QT prolonging drugs, such as amiodarone, presents a possible risk of torsades de pointes (TDP) and nodal agents may cause bradycardia (Table 2 ) [ 30 •].…”

Section: Ventricular Arrhythmiasmentioning

confidence: 99%

Management of Arrhythmias Associated with COVID-19

et al. 2020

View full text Add to dashboard Cite

Purpose of Review Cardiac arrhythmias are known complications in patients with COVID-19 infection that may persist even after recovery from infection. A review of the spectrum of cardiac arrhythmias due to COVID-19 infection and current guidelines and assessment or risk and benefit of management considerations is necessary as the population of patients infected and covering from COVID-19 continues to grow. Recent Findings Cardiac arrhythmias such as atrial fibrillation, supraventricular tachycardia, complete heart block, and ventricular tachycardia occur in patients infected, recovering and recovered from COVID-19. Summary Personalized care while balancing risk/benefit of medical or invasive therapy is necessary to improve care of patients with arrhythmias. Providers must provide thorough follow-up care and use necessary precaution while caring for COVID-19 patients.

show abstract

“…Interruptions in tube feeding and varying vitamin K content, as well as initiation/discontinuation of antibiotics, steroids, and antiviral medications, can lead to fluctuations in the international normalized ratio. 64 , 65 However, due to the ease of monitoring, warfarin remains a viable option once a patient has recovered and is no longer receiving drugs affecting warfarin metabolism. Direct oral anticoagulants, such as anti-Xa inhibitors or dabigatran, may be considered for long-term anticoagulation but should be used with caution in the acutely ill COVID-19 population due to potential drug-drug interactions, administration limitations, and impaired absorption.…”

Section: Managementmentioning

confidence: 99%

Cardiac Arrhythmias in Critically Ill Patients With COVID-19: A Brief Review

Karamchandani

Quintili

Landis

et al. 2021

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2, is now a global pandemic affecting more than 12 million patients across 188 countries. A significant proportion of these patients require admission to intensive care units for acute hypoxic respiratory failure and are at an increased risk of developing cardiac arrhythmias. The presence of underlying comorbidities, pathophysiologic changes imposed by the disease, and concomitant polypharmacy, increase the likelihood of life-threatening arrhythmias in these patients. Supraventricular, as well as ventricular arrhythmias, are common and are associated with significant morbidity and mortality. It is important to understand the interplay of various causal factors while instituting strategies to mitigate the impact of modifiable risk factors. Furthermore, avoidance and early recognition of drug interactions, along with prompt treatment, might help improve outcomes in this vulnerable patient population.

show abstract

Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019

Cited by 37 publications

References 60 publications

Arrhythmias and COVID-19

Arrhythmias and COVID-19

Management of Arrhythmias Associated with COVID-19

Cardiac Arrhythmias in Critically Ill Patients With COVID-19: A Brief Review

Contact Info

Product

Resources

About